279 related articles for article (PubMed ID: 22856540)
21. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
[TBL] [Abstract][Full Text] [Related]
22. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder.
Hassan M; Madhavan SS; Kalsekar ID; Makela EH; Rajagopalan K; Islam S; Kavookjian J; Miller LA
Ann Pharmacother; 2007 Nov; 41(11):1812-8. PubMed ID: 17925501
[TBL] [Abstract][Full Text] [Related]
23. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
[TBL] [Abstract][Full Text] [Related]
24. A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients.
Vázquez-Bourgon J; Ibáñez Alario M; Mayoral-van Son J; Gómez Revuelta M; Ayesa Arriola R; Juncal Ruiz M; Ortiz-García de la Foz V; Crespo Facorro B
Eur Neuropsychopharmacol; 2020 Oct; 39():46-55. PubMed ID: 32891516
[TBL] [Abstract][Full Text] [Related]
25. Predictors of aripiprazole treatment continuation in hospitalized patients.
Coley KC; Fabian TJ; Kim E; Ammerman DK; Scipio TM; Saul MI; Kim MS; Whitehead R; Ganguli R
J Clin Psychiatry; 2008 Sep; 69(9):1393-7. PubMed ID: 19012819
[TBL] [Abstract][Full Text] [Related]
26. Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.
Jing Y; Johnston SS; Fowler R; Bates JA; Forbes RA; Hebden T
J Med Econ; 2011; 14(6):777-86. PubMed ID: 21954966
[TBL] [Abstract][Full Text] [Related]
27. The case for atypical antipsychotics in bipolar disorder.
Shattell M; Keltner NL
Perspect Psychiatr Care; 2004; 40(1):34-8. PubMed ID: 15147051
[TBL] [Abstract][Full Text] [Related]
28. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
Rajagopalan K; Wade S; Meyer N; Loebel A
Curr Med Res Opin; 2017 May; 33(5):813-820. PubMed ID: 28098496
[TBL] [Abstract][Full Text] [Related]
29. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.
Citrome L; Kalsekar I; Guo Z; Laubmeier K; Hebden T
Clin Ther; 2013 Dec; 35(12):1867-75. PubMed ID: 24119767
[TBL] [Abstract][Full Text] [Related]
30. One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis.
Kim E; You M; Pikalov A; Van-Tran Q; Jing Y
BMC Psychiatry; 2011 Jan; 11():6. PubMed ID: 21214937
[TBL] [Abstract][Full Text] [Related]
31. Epidemiologic study of aripiprazole use and the incidence of suicide events.
Ulcickas Yood M; Delorenze G; Quesenberry CP; Tsai AL; Phillips S; Willey VJ; Niemcryk SJ; Wells K; Skovron ML; Cziraky MJ; Carson W; Oliveria SA
Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1124-30. PubMed ID: 20925132
[TBL] [Abstract][Full Text] [Related]
32. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
[TBL] [Abstract][Full Text] [Related]
33. The treatment of mixed states and the risk of switching to depression.
Vieta E
Eur Psychiatry; 2005 Mar; 20(2):96-100. PubMed ID: 15797692
[TBL] [Abstract][Full Text] [Related]
34. Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.
Goikolea JM; Colom F; Torres I; Capapey J; Valentí M; Undurraga J; Grande I; Sanchez-Moreno J; Vieta E
J Affect Disord; 2013 Jan; 144(3):191-8. PubMed ID: 23089129
[TBL] [Abstract][Full Text] [Related]
35. Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Perlis RH
Am J Manag Care; 2007 Nov; 13(7 Suppl):S178-88. PubMed ID: 18041879
[TBL] [Abstract][Full Text] [Related]
36. Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis.
Kim E; Maclean R; Ammerman D; Jing Y; Pikalov A; You M; Van-Tran Q; L'Italien G
Clin Ther; 2009 Apr; 31(4):836-48. PubMed ID: 19446157
[TBL] [Abstract][Full Text] [Related]
37. Managing the acutely agitated and psychotic patient.
Nordstrom K; Allen MH
CNS Spectr; 2007 Oct; 12(10 Suppl 17):5-11. PubMed ID: 17934384
[TBL] [Abstract][Full Text] [Related]
38. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
[TBL] [Abstract][Full Text] [Related]
39. Long-term use of atypical antipsychotics in bipolar disorder.
Ehret MJ; Levin GM
Pharmacotherapy; 2006 Aug; 26(8):1134-47. PubMed ID: 16863489
[TBL] [Abstract][Full Text] [Related]
40. A model of anticholinergic activity of atypical antipsychotic medications.
Chew ML; Mulsant BH; Pollock BG; Lehman ME; Greenspan A; Kirshner MA; Bies RR; Kapur S; Gharabawi G
Schizophr Res; 2006 Dec; 88(1-3):63-72. PubMed ID: 16928430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
